In vivo mouse cardiac hyperpolarized magnetic resonance spectroscopy by Michael S Dodd et al.
Dodd et al. Journal of Cardiovascular Magnetic Resonance 2013, 15:19
http://www.jcmr-online.com/content/15/1/19RESEARCH Open AccessIn vivo mouse cardiac hyperpolarized magnetic
resonance spectroscopy
Michael S Dodd1,2*, Vicky Ball1, Rosalind Bray1, Houman Ashrafian2, Hugh Watkins2, Kieran Clarke1
and Damian J Tyler1Abstract
Background: Alterations in cardiac metabolism accompany many diseases of the heart. The advent of cardiac
hyperpolarized magnetic resonance spectroscopy (MRS), via dynamic nuclear polarization (DNP), has enabled a
greater understanding of the in vivo metabolic changes that occur as a consequence of myocardial infarction,
hypertrophy and diabetes. However, all cardiac studies performed to date have focused on rats and larger animals,
whereas more information could be gained through the study of transgenic mouse models of heart disease.
Translation from the rat to the mouse is challenging, due in part to the reduced heart size (1/10th) and the
increased heart rate (50%) in the mouse compared to the rat.
Methods and Results: In this study, we have investigated the in vivo metabolism of [1-13C]pyruvate in the mouse
heart. To demonstrate the sensitivity of the method to detect alterations in pyruvate dehydrogenase (PDH) flux,
two well characterised methods of PDH modulation were performed; overnight fasting and infusion of sodium
dichloroacetate (DCA). Fasting resulted in an 85% reduction in PDH flux, whilst DCA infusion increased PDH flux by
123%. A comparison of three commonly used control mouse strains was performed revealing significant metabolic
differences between strains.
Conclusions: We have successfully demonstrated a hyperpolarized DNP protocol to investigate in vivo alterations
within the diseased mouse heart. This technique offers a significant advantage over existing in vitro techniques as it
reduces animal numbers and decreases biological variability. Thus [1-13C]pyruvate can be used to provide an in vivo
cardiac metabolic profile of transgenic mice.Background
Genetic mouse models have proved to be an invaluable tool
in understanding and assessing the metabolic basis of heart
disease. Transgenic and knockout (KO) mouse lines enable
individual metabolic pathways to be probed, yielding valuable
insights into the etiology of human heart disease. Mouse
models such as the long chain acyl-CoA dehydrogenase-
KO [1,2], peroxisome proliferator-activated receptor α-KO
[3] and glucose transporter 1 [4] transgenic models, have
increased our knowledge of the development and pathology
of human heart diseases. The ability to target individual
enzymes or complexes allows a greater understanding of* Correspondence: michael.dodd@dpag.ox.ac.uk
1Cardiac Metabolism Research Group, Department of Physiology, Anatomy &
Genetics, University of Oxford, Oxford, UK
2Division of Cardiovascular Medicine, Radcliffe Department of Medicine,
University of Oxford, Oxford, UK
Full list of author information is available at the end of the article
© 2013 Dodd et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the ortheir role and impact on the metabolic profile of heart dis-
ease and provide new angles for diagnosis and treatment.
Many techniques exist to assess the metabolic profile of a
diseased or transgenic animal. Ultraviolet spectroscopy, used
for over 70 years [5], allows the assessment of metabolite
concentrations or enzyme activities in tissue homogenates.
More recently, metabolomic techniques, including 1H-nu-
clear magnetic resonance (NMR), gas chromatography–
mass spectrometry (MS) and liquid chromatography-MS
have enabled detection of millimolar to sub-picomolar
changes of metabolite levels/concentrations in disease [6,7].
However, these techniques all require the collection of tissue
at specific time points, failing to allow serial measurements
to be made in the same animal during the progression of
a disease.
13C magnetic resonance spectroscopy (MRS) is par-
ticularly well suited to the study of metabolism in the
heart due to the extensive range of metabolites that cantd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from an inherently low sensitivity, which necessitates
long scan times and has limited in vivo cardiac 13C MRS
studies [9,10]. These limitations have led to a reliance on
ex vivo perfused heart models which prevents the study
of the metabolic interplay between organs, such as the
liver and heart.
A potential solution to the low sensitivity of 13C MRS has
recently been developed with the advent of hyperpolarization,
via dynamic nuclear polarization (DNP), whereby the
sensitivity of 13C MRS can be increased more than
10,000-fold [11-13]. Hyperpolarized compounds can be
infused in vivo and their metabolism visualized in real
time [14]. To date, the most successful example of a
DNP hyperpolarized molecule has been [1-13C]pyruvate
[14-23] (recently reviewed in [24]). Pyruvate, the ter-
minal molecule of glycolysis, can be processed by 3
main enzymes: pyruvate dehydrogenase (PDH), lactate
dehydrogenase (LDH) and alanine aminotransferase
(AAT). The control of these enzymes determines the
relative contribution of glucose-derived carbon into the
TCA cycle [25]. Relative fluxes through PDH into [13C]
bicarbonate and 13CO2 have been shown to correlate with
ex vivo PDH activity [19], whilst [1-13C]pyruvate’s
processing into [1-13C]lactate and [1-13C]alanine provides
a measure of the balance between glycolysis and glucose
oxidation.
However, all cardiac studies performed so far have fo-
cused on rats or larger animals, whereas more information
could be gained through the study of transgenic mouse
models of heart disease. Translation from the rat to the
mouse is challenging, due in part to the smaller heart size
(~600 [26] vs. ~80 mg [27]), which will limit the measur-
able signal, and the higher heart rate (450 vs. 600 bpm
[28]), which will increase motional artefacts and limit
spectral resolution. In this study, we have developed an
approach to investigate the metabolism of [1-13C]pyruvate
in the in vivo mouse heart. To define the sensitivity of the
developed method to detect alterations in PDH flux, mice
were scanned in either the fed state, the fasted state (after
removal of food for ~19 hours) or following an infusion of
sodium dichloroacetate (DCA). Both fasting and DCA
have been shown to modulate in vivo PDH flux in rat
hearts [14,19]. Following evaluation of the developed tech-
nique, it was used to characterize the metabolic profile of
a series of control mouse strains, C57BL/6, 129 SvEv and
balb/c mice, as these are frequently used as breeding
backgrounds for transgenic mouse lines [29,30].
The recent development of hyperpolarized 13C MRS
has led to the first human trials of the technique in the
study of prostate cancer at the University of California,
San Francisco. This study aims to image changes in the
production of [1-13C]lactate following injection of
hyperpolarized [1-13C]pyruvate in the prostate, to detectalterations in tumour metabolism (Clinical trial identi-
fier: NCT01229618 [31-33]). As recently reviewed by
Schroeder et al. (2011) there are a wide variety of poten-
tial applications for hyperpolarized 13C MRS in the study
of human cardiovascular metabolism [34]. As such, the
aim of this work was to develop hyperpolarized MRS for
mouse applications to provide a novel tool to assess the
effect of genetic alterations in the in vivo heart and to
aid in the translation of future findings to the clinic.
Methods
[1-13C]Pyruvic acid and dichloroacetic acid were
obtained from Sigma Aldrich (Sigma-Aldrich Company
Ltd. Dorset, UK). Dichloroacetic acid was neutralized
with sodium hydroxide, to form sodium DCA for injec-
tion into animals. Nineteen male C57BL/6 mice (~25 g,
15 week old), five male balb/c (~25 g, 15 week old), and
four male Wistar rats (~250 g) were obtained from
Harlan UK. Six male 129 SvEv (~25 g, 15 week old) were
obtained from stable colonies at the University of
Oxford. All animals were housed on a 12:12-h light–
dark cycle and all fed animal studies were performed be-
tween 7 a.m. and 11 a.m., during the early absorptive
(fed) state. Fasted animal scans were performed between
11 am and 1 pm following removal of food (minimum
19 hours). All investigations conformed to Home Office
Guidance on the Operation of the Animals (Scientific
Procedures) Act (HMSO) of 1986, to institutional
guidelines and was approved by the University of Oxford
Animal Ethics Review Committee.
Animal handling
Anaesthesia was induced at 2.5-3% isoflurane in oxygen
and nitrous oxide (4:1, total of 2 l/min). Anaesthesia was
maintained by means of 2% isoflurane delivered to, and
scavenged from, a nose cone during the experiment. A
catheter (32 gauge needle) was introduced into the tail
vein for intravenous infusion of hyperpolarized solutions
and animals were then placed in a home-built animal-
handling system, the same system was used for mice and
rats [35]. ECG and respiration rate were monitored
throughout the experiment and air heating was provided
to maintain body temperature.
Pyruvate polarization and dissolution
Approximately 40 mg of [1-13C]pyruvic acid doped with
15 mmol/L trityl radical (OXO63, Oxford Instruments,
Abingdon, UK) and 3 μl Dotarem (1:50 dilution)
(Guerbet, Birmingham, UK), was hyperpolarized in a
polarizer (General Electric Prototype Polarizer, GE
Healthcare, Amersham, UK), with 45 min of microwave
irradiation, as previously described [11]. The sample was
subsequently dissolved in a pressurized and heated alka-
line solution, containing 60 mmol/L sodium hydroxide
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Aldrich), to yield a solution of 80 mM hyperpolarized
sodium [1-13C]pyruvate with a polarization of ~30%, at
physiological temperature and pH [14].
Hyperpolarized 13C MRS protocol
A circular 13C RF surface transmit/receive coil was built
in-house and used for all mouse experiments in this study
(radius 10 mm). To test the sensitivity profile of the coil, a
field map was generated using an acetone phantom and
then overlaid on top of an axial proton image of a mouse
(Figure 1). The field map was calculated using a chemical
shift imaging acquisition at multiple flip angle values (TR/
TE, 1000/1.01 ms; flip angle, arrayed; Averages, 32; slice
thickness, 20 mm; matrix, 8 × 8 × 512; field of view, 64 ×
64 mm; zero-filled, 32 × 32 × 512). Sensitivity was detected
at a distance sufficient to include signal from the back
wall of the mouse heart (a depth of approximately 10 mm),
confirming that the coil was appropriate for use in this
study.
The 13C RF coil was placed over the mouse chest, local-
izing signal from the heart. Mice were positioned in a 7 T
horizontal bore MR scanner interfaced to a direct-drive
console (Varian Inc, Yarnton, UK). Using a 72 mm 1H vol-
ume transmit/receive RF coil (Rapid Biomedical, Rimpar
Germany), a 3-plane FLASH localizer image was obtained
to confirm the location of the heart at the magnet
isocentre (TR/TE, 3.67/1.63 ms; flip angle, 24°; Averages,
16; slice thickness, 2 mm; matrix, 256 × 256; field of view,
51.2 × 51.2 mm). A fiducial marker containing water,
positioned on top of the 13C RF coil, was used to ensure
the correct position of the 13C RF coil over the heart.
Using the 1H volume coil, an ECG-gated shim was used to
reduce the proton linewidth to ~150 Hz.
Following dissolution, 0.15 ml of hyperpolarized pyru-
vate was injected over 10 s into the anesthetised mouse
(dose of 0.48 mmol/kg), followed by a 0.05 ml flush of
heparinized saline to clear the delivery line [21]. Sixty in-
dividual ECG-gated 13C MR pulse-acquire cardiac spec-
tra were acquired over 1 min following injection (TR,Figure 1 13C field map of the mouse radiofrequency coil. Correct posit
the heart. This field map shows the sensitivity of the transmit/receive coil t
maximum of 1.1 s; excitation flip angle, 15° at the front wall of the
heart, assessed using the previously generated field map;
sweep width, 8,012 Hz; acquired points, 2,048; frequency
centred on the C1 pyruvate resonance).
Development of mouse cardiac DNP using C57BL/6 mice
Male C57BL/6 mice (body weight (BW) = ~25 g)
received [1-13C]pyruvate scans, in either the fed state
(n = 7) or after fasting overnight for a minimum of
19 hours (n = 7). Another group of C57BL/6 mice
(n = 5) received [1-13C]pyruvate scans after an infusion
of DCA (30 mg/kg, in saline at pH 7.4). DCA (0.2 ml)
was injected as a bolus into the tail vein cannula,
followed by an infusion of 0.1 ml over 10 minutes. The
end of the infusion was timed to allow immediate injec-
tion of hyperpolarized [1-13C]pyruvate. Due to the
increased volume injected, mice were sacrificed immedi-
ately following the acquisition of the hyperpolarized
spectroscopy data.
Comparison with rats
Wistar rats have commonly been used as control animals
for hyperpolarized cardiac studies. To perform a compari-
son between the fed C57BL/6 mice and fed Wistar rats
(BW = ~250 g, dose of 0.32 mmol/kg), four male rats were
also scanned using the methods set out in [16]. Briefly, rats
were anesthetised using 2.5-3% isoflurane and maintained
at 2%. A catheter was introduced into the tail vein for i.v.
delivery of the hyperpolarized [1-13C]pyruvate solution.
Following dissolution, 1 ml of hyperpolarized pyruvate was
injected over 10 s into the anesthetised rat. Sixty individual
ECG-gated 13C MR pulse-acquire cardiac spectra were
acquired over 1 min after injection, using a custom built
13C loop butterfly RF coil (radius 20 mm) [16].
Strain comparison
Male Balb/c (n = 5, BW = ~25 g) and male 129 SvEv (n =
6, BW = ~25 g) received [1-13C]pyruvate scans in the
fed state to compare the metabolic profile in theseioning of the RF coil is vital for ensuring sensitivity to the back wall of
o 13C. The scale bar indicates relative B1 transmit profile, normalized to
Figure 2 Example mouse spectra. A) Example spectra in a fed
wild type C57BL/6 mouse, every other second is represented for
clarity. B) Summed spectrum of 40 individual spectra from a fed wild
type C57BL/6 mouse. N.B. [2-13C]pyruvate is derived from 13C natural
abundance pyruvate.
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fed C57BL/6 mice.
MRS data analysis
All cardiac 13C spectra were analysed using the
AMARES algorithm in the jMRUI software package
[36]. Spectra were DC offset-corrected based on the last
half of acquired points. The peak areas of [1-13C]pyru-
vate, [1-13C]lactate, [1-13C]alanine and [13C]bicarbonate
at each time point were quantified and used as input
data for a kinetic model. The kinetic model developed
for the analysis of hyperpolarized [1-13C]pyruvate data is
based on a model developed by [19,37].
Statistics
All results are expressed as mean ± SEM. Significant
differences between mean values were determined by one-
way analysis of variance (ANOVA) followed by Bonferroni’s
multiple comparison post-hoc test. Differences between
groups were considered significant if p < 0.05.
Results
Acquisition of [1-13C]pyruvate in the in vivo mouse heart
A typical set of spectra from a fed control mouse is shown
in Figure 2 (C57BL/6). Along with the injected [1-13C]
pyruvate, the downstream metabolites, [1-13C]lactate,
[1-13C]alanine and [13C]bicarbonate can be visualized
with 1 second temporal resolution (Figure 2A). [13C]bi-
carbonate is produced from the conversion of 13CO2 by
the carbonic anhydrase enzyme. Due to the low SNR of
the peak and a rapid exchange into [13C]bicarbonate,
13CO2 is only visible when the spectra are summed
(Figure 2B).
The appearance of pyruvate and lactate resonance in
mouse versus rat
An averaged time course of the fitted peak areas of pyru-
vate, lactate, alanine and bicarbonate from the fed
C57BL/6 mouse heart (n = 5) and the fed rat heart (n = 4)
are shown in Figure 3. Curves are normalized to the
peak pyruvate signal intensity to account for any
differences in the initial polarization and coil sensitivity.
Alanine appeared significantly earlier in the mouse
heart, compared to the rat heart (2.6 ± 0.8 s vs 6 ± 1 s,
time of arrival normalized to pyruvate arrival, p < 0.05),
bicarbonate also appeared significantly earlier in the
mouse heart (1.4 ± 0.2 s vs 2.3 ± 0.3 s, time of arrival
normalized to pyruvate arrival, p < 0.05). Maximum bi-
carbonate signal was reduced 7-fold in the mouse heart
compared to the rat heart (0.023 ± 0.001 a.u. vs 0.165 ±
0.008 a.u. bicarbonate normalized to peak pyruvate sig-
nal). This may represent a difference in PDH activity in
the mouse heart compared to the rat heart.Overnight fasting and DCA modulate PDH flux in vivo
To define the sensitivity of the DNP technique in mice,
two well characterized models of PDH flux modulation
were employed (Figure 4). Overnight fasting led to a sig-
nificant 85% reduction in 13C label incorporation into bicar-
bonate compared to fed controls (from 13 ± 2 (× 10-4) s-1 to
2.0 ± 0.5 (× 10-4) s-1, p < 0.05). No significant change was
observed in the 13C label incorporation into lactate (from
300 ± 50 (× 10-4) s-1 to 225 ± 25 (× 10-4) s-1) or 13C label in-
corporation into alanine (from 90 ± 20 (× 10-4) s-1 to 130 ±
25 (× 10-4) s-1). Infusion of 0.3 ml of 30 mg/kg DCA signifi-
cantly increased PDH flux by 123% (from 13 ± 2 (× 10-4) s-1
to 29 ± 6 (× 10-4) s-1, p < 0.001). Again no differences in 13C
label incorporation into lactate or alanine were observed.
Comparison of commonly used mouse strains
Following the successful demonstration of the sensitivity
of the mouse DNP technique, comparison of the meta-
bolic profiles of the commonly used control strains, balb/c
and 129 SvEv were compared to the data from fed C57BL/
6 mice (Figure 5). 13C label incorporation into bicarbonate
was significantly higher in the 129 SvEv, compared to both
balb/c and C57BL/6 mice. Label incorporation into lactate
was significantly lower in the balb/c mice compared to
C57BL/6. 13C label incorporation into alanine appears
elevated in the C57BL/6 mice, although this failed to reach
statistical significance, (C57BL/6 verses 129 SvEv p=0.06).
AB
Figure 3 Example mouse and rat time course. A) Shows a combined time course in control mouse hearts (C57BL/6), in which the bicarbonate
signal is reduced compared to the rat (the insert shows the bicarbonate time course expanded). B) Shows a combined time course in the rat
(Wistar) for pyruvate and the three main metabolites lactate, alanine and bicarbonate (n=4).
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In this study, we have developed a hyperpolarized MRS
technique for the assessment of cardiac metabolism in
the in vivo mouse heart, using a custom built 13C surface
transmit/receive coil. The development of mouse cardiac
DNP provided several challenges, including the require-
ment of a small 13C surface transmit/receive coil, which
due to the reduction in size of the mouse heart, when
compared to the rat heart, was required to enable
localization of signal to the heart and provide sufficient
SNR. It was also necessary to ensure that acquisitions
were ECG gated to account for the increased motion
and speed of the mouse heart. The final challenge was
creating an injection line, which would allow the delivery
of the hyperpolarized fluid, whilst not overloading the
mouse’s venous system, thereby allowing serial timepoint
measurements. Using ultra fine bore tubing and an insu-
lin needle, the dead volume in the cannula was reduced
to approximately 50 μl.
As expected, spectra acquired in wild type mice
(C57BL/6) showed similar resonances to the rat.However, carbon dioxide was only occasionally visible in
the high temporal resolution spectra. Carbon dioxide
was present in summed spectra, indicating that its ab-
sence was due to lower SNR in the mouse compared to
the rat. Pyruvate and lactate appearance mirrored that of
rats, whilst alanine signals appeared to be slightly
elevated compared to the time evolution in the rat and
also showed significant temporal differences in appear-
ance. However, the major difference between rat and
mouse spectra was the relative levels of bicarbonate pro-
duction, which were 7-fold lower in the mouse heart
compared to the rat heart when normalized to max-
imum pyruvate signal, possibly representing a species
difference in PDH expression/activity due to differences
in cardiac work load. This is supported by previous
measurements which would suggest a lower PDH activ-
ity in the mouse compared with the rat (2.4 μmol/min/g
tissue (mouse) [38] vs 5.1 μmol/min/g tissue (rat) [19]).
In this work, the sensitivity of the cardiac hyperpolarized
MRS technique was demonstrated to detect in vivo
alterations in PDH flux. Using hyperpolarized [1-13C]
Figure 4 Demonstration of hyperpolarized [1-13C]pyruvate in the in vivo mouse heart. A) Fasting in control mice significantly decreased
13C label incorporation into bicarbonate in the C57BL/6 mouse heart, compared to fed controls. Infusion of DCA significantly increase in 13C label
incorporation compared to fed mice. B) No difference was found in 13C label incorporation of lactate between fed, fasting and DCA infusion.
C) No significant difference was found between 13C label incorporation into alanine in the fed, fasted or DCA state. All results are expressed as
the mean ± SEM. * p < 0.05 and *** p < 0.001 compared to fed controls.
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flux was previously observed in the fasted state [14]. Fur-
ther, infusing 30 mg/kg of DCA was shown to significantly
increase PDH flux in Wistar rat hearts [19]. Both methods
of PDH modulation rely on alterations to the inhibitor ofFigure 5 Comparison between different mouse strains. Several commo
compared using [1-13C]pyruvate. A) Label incorporation into bicarbonate w
however significantly elevated in the 129 SvEv. B) Label incorporation into
C57BL/6. C) No difference was seen in alanine. All results are expressed as
p < 0.01 compared to Balb/c.PDH, PDH kinase (PDK) [39,40] (reviewed in [41]). Dur-
ing fasting, plasma fatty acid levels increase, insulin levels
drop and fatty acid oxidation increases in the heart
[14,42,43]. In response, PPARα is activated and increases
the expression of PDK4, which acts to “spare” pyruvate fornly used mouse strains (C57BL/6, Balb/c and 129 SvEv) were
as found to be similar between the C57BL/6 and balb/c, it was
lactate was significantly reduced in the balb/c mouse, compared to
the mean ± SEM. * p < 0.05 and ** p < 0.01 vs C57BL/6 and $$
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nificant 74% reduction in PDH flux, seen as a drop in the
total [13C]bicarbonate/[1-13C]pyruvate ratio [14]. In this
study, mice fasted overnight for a minimum of 19 hours
had an 85% decrease in PDH flux compared to control the
fed state group (p < 0.05).
The third group of mice received a DCA infusion prior
to the hyperpolarized injection. DCA has a broad inhibi-
tory action on all 4 isoforms of PDK, thereby increasing
the proportion of PDH in the active form [39,40,47]. In
rats, DCA infusion resulted in a 160% increase in PDH
flux in control animals [19]. In mice the infusion of DCA
significantly increased PDH flux by 123%, compared to
control mice (p < 0.001). Evaluation of the mouse DNP
technique proved it was sensitive to alterations in PDH
flux within the mouse heart and demonstrated the poten-
tial to use hyperpolarized MRS to investigate transgenic
mouse models of cardiac diseases in the future.
Following demonstration of the technique, we characterized
the metabolic profile of other commonly used control
mouse strains. C57BL/6, 129 SvEv and balb/c mice are
inbred mice strains used for metabolic studies and are
commonly used as breeding backgrounds for transgenic
mouse lines [29,30]. In mouse models of heart disease,
observed differences in metabolic profiles are influenced
by the background strain used to generate the mouse
[48,49]. In the study by Gavaghan et al. [49], NMR analysis
of control strain urine found that there were differences in
metabolite composition between healthy mouse strains. In
our study several differences were observed in cardiac 13C
label incorporation into metabolite pools, between these
control strains. The 129 SvEv strain had elevated 13C label
incorporation into bicarbonate, suggesting a difference in
PDH flux, when compared to C57BL/6 and balb/c mice.
13C label incorporation into lactate was reduced in the
balb/c strain compared to C57BL/6, but not compared to
129 SvEv. The strain differences presented in this paper
are supported by significant differences in glycolytic and
glucose oxidation rates and glucose uptake presented in
previous work from these three strains [29,50-52]. These
differences highlight the important requirement of
selecting both the correct mouse background and appro-
priate control animals for metabolic studies.
Conclusion
In conclusion, we have successfully developed and
demonstrated a hyperpolarized DNP protocol to investi-
gate alterations in metabolism within the in vivo mouse
heart. The use of fasting and DCA has demonstrated the
sensitivity of the technique to detect alterations in PDH
activity in the mouse heart. The technique has also
highlighted possible metabolic differences in strains of
mice commonly used for metabolic studies. This tech-
nique offers significant advantages over existing in vitrotechniques that would require collection of tissue
samples, as it can reduce animal numbers and decrease
biological variability. Thus [1-13C]pyruvate can be used
to monitor the in vivo cardiac metabolic profile of trans-
genic mice.
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